Velasco-Murillo V

Language: Spanish
References: 29
Page: 61-69
PDF size: 162.71 Kb.

ABSTRACT

Preliminary results of the American study called Women’s Health Initiative starting in July 2002, showed an increase in some health risks, such as coronary disease, stroke, invasive breast cancer and dementia in 2003, in postmenopausal users of replacement hormonal therapy (HRT) with conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA). These results were opposed to those found in many observational studies in previous years. Although some benefits like significant reduction in number of osteoporotic fractures were demonstrated too, these results caused an enormous change in medical criteria for prescription and time of usage of HRT during the climacteric and postmenopausal periods in the whole world. The publication of complementary information in subsequent years to date, related to other sections or branches of Women’s Health Initiative, such as only-estrogens users, which showed no increase of the above mentioned results, confirm the importance of continuing analysis of Women’s Health Initiative results, as well as the need to do more research about THR, with the purpose to get a better understanding about risks and benefits. This paper is a review of the most important results of Women’s Health Initiative published to date, with comments about the hypothesis and possibilities to explain them, with the purpose of spreading in a realistic way the state of knowledge in the usage of HRT and increase the information of family physicians in Instituto Mexicano del Seguro Social, who are the first contact for medical care in these periods of their lives and help them to take clinical decisions.

REFERENCES

1. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA 2002;288(3): 321-333.

2. 2. Reed SD, Newton KM, Lacroix AZ. Indications for hormone therapy: the post-Women’s Health Initiative era. Endocrinol Metab Clin Orth Am 2004;33(4):691-715.

3. 3. MacLennan AH, Taylor AW, Wilson DH. Hormone therapy after the Women’s Health Initiative. Climateric 2004;7(2):117-119.

4. 4. Writing Group for the Women’s Health Initiative Investigators. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative Randomized Controlled Trial. JAMA 2004;291(14):1701-1712.

5. 5. Ancelin ML, Berr C. Hormonal replacement therapy and Alzheimer’s disease. All quiet on the western front? Psycol Neuropsychiatr Vieil 2003;1(4):251-257.

6. 6. Azoulay C. Menopause in 2004: “hormone replacement therapy” is not what used to be anymore. Rev Med Interne 2004;25(11):806-815.

7. 7. Warren MP, Halpert S. Hormone replacement therapy: controversies, pros and cons. Best Pract Res Endocrinol Metab 2004;18(3):317-332.

8. 8. Fleming RM. Do women taking hormone replacement therapy (HRT) have a higher incidence of breast cancer than women who do not? Integr Cancer Ther 2003;2(3):235-237.

9. 9. McIntosh J, Blalock SJ. Effects of media coverage of Women’s Health Initiative Study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm 2005;62(1):69-74.

10. Hoffmann M, Lindh-Astrand L, Ahiner J, Hammar M, Kjellgren KI. Hormonal replacement therapy in the menopause. Structure and content of risk talk. Maturitas 2005;50(1):8-18.

11. Hillman JJ, Zuckerman IH, Lee E. The impact of the Women’s Health Initiative on hormone replacement therapy in a Medicaid program. J Womens Health 2004;13(9):986-992.

12. Haskell SG. After the Women’s Health Initiative: Postmenopausal women’s experiences with discontinuing estrogen replacement therapy. J Womens Health 2004;13(4):438-442.

13. McDonough PG. The randomized world is not without imperfections: reflections on the Women’s Health Initiative Study. Fertil Steril 2002;78(5): 951-956.

14. Mepherson K. Where are now with hormonal replacement therapy? Reprod Health Matters 2004; 12(24):200-203.

15. Goldman JA. The Women’s Health Initiative 2004–Review and critique. Medscape General Medicine 2004. Disponible en: www.medscape. com/viewarticle/483902.

16. Holmberg L, Anderson H. HABITS (Hormonal replacement therapy after breast cancer is-it-safe?) a randomized comparison: trial stopped. Lancet 2004; 363(9407): 410-411.

17. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362(9832):419-427.

18. Velasco-Murillo V. Terapia hormonal de reemplazo. Consideraciones sobre los hallazgos de 2002. Rev Med IMSS 2003;41(4):321-327.

19. Maclennan AH, Boradbent JL, Lester S, Moore V. Oral estrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;(4):CD002978.

20. Blumel JE, Castelo-Branco C, Chedraui PA, Binfa I, Dowlani B, Gomez MS, et al. Patients’ and clinicians’ attitudes after the Women’s Health Initiative study. Menopause 2004;11(1):57-61.

21. Vogelvang TE, Van der Mooren MJ, Mijatovic V. Hormone replacement therapy, selective estrogen receptors modulators, and tissue-specific com-pounds: cardiovascular effects and clinical impli-cations. Treat Endocrinol 2004;3(2):105-115.

22. Silvestri A, Gambacciani M, Vitale C, Monteleone P, Ciaponi M, Fini M et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas 2005; 50(4):305-311.

23. Smith NI, Heckbert SR, Lemaitre RN, Rozenn NL, Reiner AP, Lumley T, Weiss NS, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004;292(13):1581-1587.

24. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13(10):1558-1568.

25. Wren BG. Do female sex hormones initiate breast cancer? A review of the evidence. Climateric 2004; 7(2):120-128.

26. Basavilvazo-Rodríguez MA, Diaz-Quiroz A, Lemus-Rocha M, Angeles-Victoria L, Zárate A, Hernández-Valencia M. Terapia hormonal de reemplazo y cáncer mamario. Un estudio de casos y controles. Ginecol Obstet Mex 2004;72(1):10-15.

27. Pujol P, This P, Noruzinia M, Stoppa-Lyonnet D, Maudelonden T. Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens? Bull Cancer 2004;91(7):583-591.

28. Aubuchon M, Santoro N. Lessons learned from the Women’s Health Initiative: HRT requires a cautious and individualized approach. Geriatrics 2004;59 (11):22-26.

29. Prelevic GM, Kocjan T, Markou A. Hormone replacement therapy in postmenopausal women. Minerva Endocrinol 2005;30(1):27-36.